NRx Pharmaceuticals receives FDA approval for preservative-free ketamine ANDA

NRx Pharmaceuticals received FDA approval of its Abbreviated New Drug Application for preservative-free ketamine, ahead of the November 10 goal date. The company will manufacture the drug in the US using blow-fill-seal technology in partnership with Nephron Pharmaceuticals, aiming to address supply shortages of traditional glass-bottled ketamine.

Detected & updated continuously · Source: Nebula